Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
Open accessAbstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting from chemotherapy for cancer. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and the prevalence of CIPN is not known. Here we used a systematic review to identify studies reporting the prevalence of CIPN. We searched Embase, Medline, CAB Abstracts, CINAHL, PubMed central, Cochrane Library, and Web of Knowledge for relevant references and used random-effects meta-regression to estimate overall prevalence. We assessed study quality using the CONSORT and STROBE guidelines, and we report findings according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. We provide a qualitative summary of factors reported to alter the risk of CIPN. We included 31 studies with data from 4179 patients in our analysis. CIPN prevalence was 68.1% (57.7-78.4) when measured in the first month after chemotherapy, 60.0% (36.4-81.6) at 3months and 30.0% (6.4-53.5) at 6months or more. Different chemotherapy drugs were associated with differences in CIPN prevalence, and there was some evidence of publication bias. Genetic risk factors were reported in 4 studies. Clinical risk factors, identified in 4 of 31 studies, included neuropathy at baseline, smoking, abnormal creatinine clearance, and specific sensory changes during chemotherapy. Although CIPN prevalence decreases with time, at 6months 30% of patients continue to suffer from CIPN. Routine CIPN surveillance during post-chemotherapy follow-up is needed. A number of genetic and clinical risk factors were identified that require further study.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CIPN is a common cause for early cessation of cancer treatment and affects up to 70% of patients receiving chemotherapy.
“It is a common cause for early cessation of cancer treatment and affects up to 70% of patients receiving chemotherapy (Seretny et al, 2014).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Seretny et al, 2014
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · see citing works
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859 · see citing works
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020 · see citing works
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320 · see citing works
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575 · see citing works
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · see citing works
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835 · see citing works
Neuropathic pain: aetiology, symptoms, mechanisms, and management
Woolf, C. J., & Mannion, R. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01307-0 · Cited by 2,231 · see citing works
Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage
Costigan, M., Scholz, J., & Woolf, C. J. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135531 · Cited by 2,025 · see citing works
Prognosis and prognostic research: validating a prognostic model
Altman, D. G., Vergouwe, Y., Royston, P., & Moons, K. G. M. (2009) · BMJ · doi:10.1136/bmj.b605 · Cited by 1,436 · see citing works
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Smith, E., Bleeker, J. S., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,210 · see citing works
Smith, E., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Ahles, T. A., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N. A., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,016 · see citing works
Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms
von Hehn, C. A., Baron, R., & Woolf, C. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.02.008 · Cited by 804 · see citing works
Immune and inflammatory mechanisms in neuropathic pain
Moalem‐Taylor, G., & Tracey, D. J. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.11.004 · Cited by 772 · see citing works
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S.-Y., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 745 · see citing works
Grisold, W., Cavaletti, G., & Windebank, A. J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos203 · Cited by 487 · see citing works
Kemp, G. J., Rose, P. S., Lurain, J. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2101 · Cited by 468 · see citing works
Chemotherapy-induced neuropathy: A comprehensive survey
Miltenburg, N. C., & Boogerd, W. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.04.004 · Cited by 446 · see citing works
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421 · see citing works
Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy
Rao, R. D., Michalak, J. C., Sloan, J. A., Loprinzi, C. L., Soori, G. S., Nikcevich, D. A., Warner, D. O., Novotny, P. J., Kutteh, L. A., Wong, G. Y., et al. (2007) · Cancer · doi:10.1002/cncr.23008 · Cited by 360 · see citing works
Chemotherapy-induced peripheral neurotoxicity
Cavaletti, G., & Marmiroli, P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.160 · Cited by 353 · see citing works
Fallon, M. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet208 · Cited by 328 · see citing works
Self-citationNeuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy
Pace, A., Savarese, A., Picardo, M., Maresca, V., Pacetti, U., Monte, G. D., Biroccio, A., Leonetti, C., Jandolo, B., Cognetti, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.139 · Cited by 308 · see citing works
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub4 · Cited by 302 · see citing works
Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A. A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds329 · Cited by 291 · see citing works
Self-citationPrevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
van der Hoop, R. G., Vecht, C. J., van der Burg, M. E. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220204 · Cited by 288 · see citing works
Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
Pachman, D. R., Barton, D. L., Watson, J. C., & Loprinzi, C. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.115 · Cited by 269 · see citing works
Hammack, J. E., Michalak, J. C., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Soori, G. S., Tirona, M. T., Rowland, K. M., Stella, P. J., & Johnson, J. A. (2002) · Pain · doi:10.1016/s0304-3959(02)00047-7 · Cited by 230 · see citing works
Oxaliplatin‐induced neurotoxicity and the development of neuropathy
Krishnan, A. V., Goldstein, D., Friedlander, M. L., et al. (2005) · Muscle & Nerve · doi:10.1002/mus.20340 · Cited by 216 · see citing works
Park, S. S., Krishnan, A. V., Lin, C. S.-Y., et al. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786848569 · Cited by 208 · see citing works
Baldwin, R. M., Owzar, K., Zembutsu, H., Chhibber, A., Kubo, M., Jiang, C., Watson, D. M., Eclov, R. J., Mefford, J., McLeod, H. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1590 · Cited by 204 · see citing works
Pike, C. T., Birnbaum, H. G., Muehlenbein, C. E., et al. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/913848 · Cited by 203 · see citing works
Attal, N., Bouhassira, D., Gautron, M., Vaillant, J.-N., Mitry, E., Lepère, C., Rougier, P. R., & Guirimand, F. (2009) · Pain · doi:10.1016/j.pain.2009.03.024 · Cited by 196 · see citing works
Vitamin E neuroprotection for cisplatin neuropathy
Pace, A., Giannarelli, D., Galiè, E., Savarese, A., Carpano, S., Giulia, M. D., Pozzi, A., Silvani, A., Gaviani, P., Scaioli, V., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d5279e · Cited by 192 · see citing works
Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathy
Rao, R. D., Flynn, P. J., Sloan, J. A., Wong, G. Y., Novotny, P. J., Johnson, D. B., Gross, H. M., Renno, S. I., Nashawaty, M., & Loprinzi, C. L. (2008) · Cancer · doi:10.1002/cncr.23482 · Cited by 191 · see citing works
Users' Guides to the Medical Literature XVI. How to Use a Treatment Recommendation
Guyatt, G. H. (1999) · JAMA · doi:10.1001/jama.281.19.1836 · Cited by 182 · see citing works
Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy
Wallace, V. C. J., Blackbeard, J., Pheby, T., Segerdahl, A. R., Davies, M., Hasnie, F. S., Hall, S., McMahon, S. B., & Rice, A. S. C. (2007) · Pain · doi:10.1016/j.pain.2007.02.015 · Cited by 172 · see citing works
Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy
Chaudhry, V., Cornblath, D. R., Polydefkis, M. J., Ferguson, A. K., & Borrello, I. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00193.x · Cited by 172 · see citing works
Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., Hashemzade, S., Jafarabadi, M. A., Montazeri, V., Keshavarz, S. A., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-355 · Cited by 171 · see citing works
Carlucci, M. T. O., Bráz, J. R. C., do Nascimento, P., de Carvalho, L. R., Castiglia, Y. M. M., & Braz, L. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090125 · Cited by 158 · see citing works
Cascinu, S., Cordella, L., Ferro, E. D., Fronzoni, M., & Catalano, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.26 · Cited by 158 · see citing works
Glendenning, J., Barbáchano, Y., Norman, A. R., Dearnaley, D. P., Horwich, A., & Huddart, R. A. (2010) · Cancer · doi:10.1002/cncr.24981 · Cited by 153 · see citing works
Dimopoulos, M. A., Mateos, M., Richardson, P. G. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kropff, M. H., Špıčka, I., Palumbo, A. P., Wu, K. L., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01533.x · Cited by 142 · see citing works
Neuropathy in multiple myeloma treated with thalidomide
Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267271.18475.fe · Cited by 126 · see citing works
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
Cavaletti, G., Alberti, P., & Marmiroli, P. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70131-0 · Cited by 123 · see citing works
Lin, P., Lee, M.-Y., Wang, W.-S., et al. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0018-9 · Cited by 113 · see citing works
Argyriou, A. A., Velasco, R., Briani, C., Cavaletti, G., Bruna, J., Alberti, P., Cacciavillani, M., Lonardi, S., Santos, C., Cortinovis, D. L., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds208 · Cited by 102 · see citing works
Johnson, D. C., Corthals, S. L., Walker, B. A., Ross, F. M., Gregory, W. M., Dickens, N. J., Lokhorst, H. M., Goldschmidt, H., Davies, F. E., Durie, B. G. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0792 · Cited by 102 · see citing works
Planting, A. S. T., Catimel, G., Mulder, P. H. M. D., de Graeff, A., Höppener, F., Verweij, I., Oster, W., & Vermorken, J. B. (1999) · Annals of Oncology · doi:10.1023/a:1008353505916 · Cited by 99 · see citing works
Lema, M. J., Foley, K. M., & Hausheer, F. H. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-s505 · Cited by 93 · see citing works
Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis
von Schlippe, M., Fowler, C. J., & Harland, S. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2006 · Cited by 91 · see citing works
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub3 · Cited by 86 · see citing works
Argyriou, A. A., Polychronopoulos, P., Koutras, A. K., et al. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0868-6 · Cited by 84 · see citing works
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., et al. (2007) · Acta Oncologica · doi:10.1080/02841860701355055 · Cited by 84 · see citing works
Won, H., Lee, J., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kim, J., Lee, S., & Park, S. H. (2011) · Cancer · doi:10.1002/cncr.26614 · Cited by 80 · see citing works
Gandara, D. R., Nahhas, W. A., ADELSON, M. D., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.490 · Cited by 70 · see citing works
Milla, P., Airoldi, M., Weber, G., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832a2dc1 · Cited by 68 · see citing works
Ishibashi, K., Okada, N., Miyazaki, T., Sano, M., & Ishida, H. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-009-0015-3 · Cited by 60 · see citing works
Boland, E. G., Selvarajah, D., Hunter, M. D., Ezaydi, Y., Tesfaye, S. H., Ahmedzai, S. H., Snowden, J. A., & Wilkinson, I. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096474 · Cited by 59 · see citing works
Argyriou, A. A., Polychronopoulos, P., Koutras, A. K., et al. (2007) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2006.00718.x · Cited by 49 · see citing works
Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?
Pace, A., Nisticò, C., Cuppone, F., et al. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.010 · Cited by 45 · see citing works
Kawakami, K., Tunoda, T., Takiguchi, T., et al. (2012) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504012x13522227232192 · Cited by 41 · see citing works
Peripheral neuropathic pain: signs, symptoms, mechanisms, and causes: are they linked?
Colvin, L., & Dougherty, P. M. (2014) · British Journal of Anaesthesia · doi:10.1093/bja/aeu323 · Cited by 24 · see citing works
Self-citationGenes, molecules and patients—Emerging topics to guide clinical pain research
Sikandar, S., Patel, R., Patel, S., Sikander, S., Bennett, D., & Dickenson, A. H. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.069 · Cited by 12 · see citing works
Chemotherapy‐Induced Polyneuropathy: Major Agents and Assessment by Questionnaires
Zedan, A. H., & Vilholm, O. J. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12262 · Cited by 11 · see citing works
Role of calcium and magnesium infusion in prevention of oxaliplatin neurotoxicity. A phase III trial
Gobran, N. S. (2013) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-013-1161-7 · Cited by 8 · see citing works
Mitchell, P., Goldstein, D. S., Michael, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3581 · Cited by 7 · see citing works
Turner, E. L., Sweeting, M. J., Lindfield, R., et al. (2013) · Statistics in Medicine · doi:10.1002/sim.5942 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355 · see citing works
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301 · see citing works
Management of common clinical problems experienced by survivors of cancer
Emery, J., Butow, P., Lai-Kwon, J., Nekhlyudov, L., Rynderman, M., & Jefford, M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00242-2 · Cited by 326 · see citing works
Duregon, F., Vendramin, B., Bullo, V., Gobbo, S., Cugusi, L., Di Blasio, A., Neunhaeuserer, D., Zaccaria, M., Bergamin, M., & Ermolao, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.002 · Cited by 196 · see citing works
Tamoxifen induces cellular stress in the nervous system by inhibiting cholesterol synthesis
Denk, F., Ramer, L. M., Erskine, E. L. K. S., Nassar, M. A., Bogdanov, Y., Signore, M., Wood, J. N., McMahon, S. B., & Ramer, M. S. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0255-6 · Cited by 44 · see citing works
Chemical modulation of Kv7 potassium channels
Borgini, M., Mondal, P., Liu, R., & Wipf, P. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00328j · Cited by 37 · see citing works
Transition from Acute to Chronic Pain: Where Cells, Systems and Society Meet
Glare, P., Overton, S., & Aubrey, K. (2020) · Pain Management · doi:10.2217/pmt-2019-0039 · Cited by 20 · see citing works
- Authors
- Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M.
- Affiliations
- Western General Hospital (GB)
- University of Edinburgh (GB)
- Edinburgh Cancer Research (GB)
- Corresponding author
- Seretny, Marta
- ORCID
- Venue
- Pain
- Published
- 2014-12
- Volume
- 155
- Issue
- 12
- Pages
- 2461-2470
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2114458368
- Semantic Scholar
- 127f093e36189affa4d2efddcd0359fb0b4755c8
- Cited by
- 1,555
- References
- 69
- Citations by year
- 2026: 142 · 2025: 190 · 2024: 169 · 2023: 160 · 2022: 187 · 2021: 171 · 2020: 145 · 2019: 140 · 2018: 101 · 2017: 84 · 2016: 38 · 2015: 24 · 2014: 2
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Pain (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Wellcome Trust
- STMTI
- National Centre for the Replacement, Refinement and Reduction of Animals in Research
- Seventh Framework Programme
- Melville Trust
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
- Keywords
- chemotherapy-induced peripheral neuropathy, prevalence, incidence, risk factors, genetic risk factors, clinical risk factors, chemotherapy drugs, neuropathic pain, cancer chemotherapy
- MeSH terms
- Drug Therapy, Humans, Peripheral Nervous System Diseases, Predictive Value of Tests, Databases, Bibliographic, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
